Tempest Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview

Tempest Therapeutics

06/05/2024 13:14

* Tempest Therapeutics Inc  TPST.OQ   TPST.O  is expected
to show
no change in quarterly revenue when it reports  results on May 8
(estimated) for the period ending March 31 2024
    * 
    * ​LSEG's mean analyst estimate for Tempest Therapeutics Inc
is
for a loss of 37 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 1.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Tempest
Therapeutics Inc is $14.00​, above​ its last closing price
of $3.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.37       -0.39      -0.38     Beat    1.5
 Sep. 30 2023  -0.56       -0.57      -0.48     Beat    16.2
 Jun. 30 2023  -0.55       -0.52      -0.54     Missed  -4.3​
 Mar. 31 2023  -0.65       -0.64      -0.55     Beat    14.4
 ​​Dec.                    -0.76      -0.63     Beat    17
 31 2022                                                
 Sep. 30 2022  -0.81       -0.80      -0.66     Beat    17.8​
 Jun. 30 2022  -0.93       -0.92      -0.79     Beat    14.4
 Mar. 31 2022  -1.12       -1.12      -1.18     Missed  -5.7
 This summary was machine generated May 6 at 12:14 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)